Εμφανίζονται 1 - 20 Αποτελέσματα από 67 για την αναζήτηση '"симптоматическая терапия"', χρόνος αναζήτησης: 0,70δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
    Academic Journal

    Πηγή: Meditsinskiy sovet = Medical Council; № 18 (2024); 133-138 ; Медицинский Совет; № 18 (2024); 133-138 ; 2658-5790 ; 2079-701X

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/8690/7629; Tran NP, Vickery J, Blaiss MS. Management of rhinitis: Allergic and non-allergic. Allergy Asthma Immunol Res. 2011;3(3):148-156. https://doi.org/10.4168/aair.2011.3.3.148.; Cemal Cingi C, Bayar Muluk N, Hanci D, Sahin E. Impacts of allergic rhinitis in social communication, quality of life and behaviours of the patients. J Allergy Disord Ther. 2015;2(1):1-3. https://doi.org/10.24966/ADT-749X/100002.; Small P, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2011;7(Suppl. 1):S3. https://doi.org/10.1186/1710-1492-7-S1-S3.; Settipane RA, Kaliner MA. Nonallergic Rhinitis. Am J Rhinol Allergy. 2013;27(Suppl. 3):S48-S51. https://doi.org/10.2500/ajra.2013.27.3927.; Kaliner MA. Classification of Nonallergic Rhinitis Syndromes With a Focus on Vasomotor Rhinitis, Proposed to be Known henceforth as Nonallergic Rhinopathy. World Allergy Organ J. 2009;2(6):98-101. https://doi.org/10.1097/WOX.0b013e3181a9d55b.; Agnihotri NT, McGrath KG. Allergic and nonallergic rhinitis. Allergy Asthma Proc. 2019;40(6):376-379. https://doi.org/10.2500/aap.2019.40.4251.; Alromaih S, Alsagaf L, Aloraini N, Alrasheed A, Alroqi A, Aloulah M et al. DrugInduced Rhinitis: Narrative Review. Ear Nose Throat J. 2022;1455613221141214. https://doi.org/10.1177/01455613221141214.; Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657-1665. https://doi.org/10.1111/all.13200.; Liva GA, Karatzanis AD, Prokopakis EP. Review of Rhinitis: Classification, Types, Pathophysiology. J Clin Med. 2021;10(14):3183. https://doi.org/10.3390/jcm10143183.; Varghese M, Glaum MC, Lockey RF. Drug-induced rhinitis. Clin Exp Allergy. 2010;40(3):381-384. https://doi.org/10.1111/j.1365-2222.2009.03450.x.; Pinargote P, Guillen D, Guarderas JC. ACE inhibitors: upper respiratory symptoms. BMJ Case Rep. 2014;2014:bcr2014205462. https://doi.org/10.1136/bcr-2014-205462.; Wahid NWB, Shermetaro C. Rhinitis Medicamentosa In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://pubmed.ncbi. nlm.nih.gov/30855902/.; Malm L, Anggard L. Vasoconstrictors. In: Mygind N, Naclerio RM (eds.). Allergic and non-allergic rhinitis. Clinical aspects. 1st ed. Copenhagen: Munksgaard; 1993, pp. 95-100. Available at: https://archive.org/details/allergicnonaller0000unse/page/n5/mode/2up.; Карпищенко СА, Колесникова ОМ. Плюсы и минусы назальных деконгестантов Педиатрия. Consilium Medicum. 2016;(3):31-36. Режим доступа: https://omnidoctor.ru/upload/iblock/958/9583c8bad29d42bcd02e93038a0a9da2.pdf.; Sutrisna В, Frerichs RR, Reingold AL. Randomised, controlled trial of effectiveness of ampicillin in mild acute respiratory infections in Indonesian children. Lancet. 1991;338(8765):471-474. https://doi.org/10.1016/01406736(91)90544-y.; Passali D, Salerni L, Passali GC, Passali FM, Bellussi L. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf. 2006;5(6):783-790. https://doi.org/10.1517/14740338.5.6.783.; Колесникова ОМ. Роль вазомоторной формы дисфункции эндотелия в патогенезе вазомоторного и аллергического ринитов: автореф. дис канд. мед. наук: 14.00.04, 14.00.16. СПб.; 2008. 10 с. Режим доступа: https://new-disser.ru/_avtoreferats/01004068137.pdf.; Lacroix JS. Adrenergic and nonadrenergic mechanisms in sympathetic vascular control of the nasal mucosa. Acta Physiol Scand Suppl. 1989;581:1-63. Available at: https://pubmed.ncbi.nlm.nih.gov/2568728/.; Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med. 2005;4(1):21-29. https://doi.org/10.2165/00151829-200504010-00003.; Graf P, Hallen H. Effect on the nasal mucosaof long-term treatment with oxymetasoline, bensalconium chloride, and placebo nasal sprays. Laryngoscope. 1996;106(5):605-609. https://doi.org/10.1097/00005537199605000-00016.; Lockey RF. Rhinitis medicamentosa and the stuffy nose. J Allergy Clin Immunol. 2006;118(5):1017-1018. https://doi.org/10.1016/j.jaci.2006.06.018.; Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol. 2006;16(3):148-155. Available at: https://www.jiaci.org/Summary/vol16-issue3-num52.; Varricchio A, Capasso M, De Lucia A, Avvisati F, Varricchio AM, Bettoncelli G, Ciprandi G. Intranasal flunisolide treatment in patients with non-allergic rhinitis. Int J Immunopathol Pharmacol. 2011;24(2):401-409. https://doi.org/10.1177/039463201102400213.; Шиленкова ВВ. Медикаментозный ринит. Медицинский совет. 2017;(8):112-115. https://doi.org/10.21518/2079-701X-2017-8-112-115.; Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol. 2000;106(4 Suppl.):S179-S190. https://doi.org/10.1067/mai.2000.110038.; Jacobs R, Lieberman P, Kent E, Silvey M, Locantore N, Philpot EE. Weather temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment. Allergy Asthma Proc. 2009;30(2):120-127. https://doi.org/10.2500/aap.2009.30.3206.; Blom HM, Godthelp T, Fokkens WJ, KleinJan A, Mulder PG, Rijntjes E. The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis. J Allergy Clin Immunol. 1997;100(6 Pt 1):739-747. https://doi.org/10.1016/s0091-6749(97)70267-7.; Lundblad L, Sipila P, Farstad T, Drozdziewicz D. Mometasone furoate nasal spray in the treatment of perennial non-allergic rhinitis: a nordic, multicenter, randomized, double-blind, placebo-controlled study. Acta Otolaryngol. 2001;121(4):505-509. Available at: https://pubmed.ncbi.nlm.nih.gov/11508513/.; Коннерт БД, Майвальд Й. Терапия хронических медикаментозных и вазомоторных ринопатий опыт применения биологического спрея для носа. Биологическая медицина. 1997;(1):23-28. Режим доступа: https://www.arnebia.ru/cgi-bin/download.cgi?id_dnl=965.; Sprenger F. Rhinitis-Behandlung. Eine Studie mit Euphorbium-compositumNasentropfen-(Heel-) Dosierspray ohne Treibgas. Z Allgemeinmed. 1984;60:1164-1168.; Heine H. Zum antiviralen Wirkmechanismus von Euphorbium compositum S. Biol Med. 2001;30:209-210.; Glatthaar-Saalmuller B, Fallier-Becker P. Antiviralaction of Euphorbium compositum and its components. Forsch Komplementarmed Klass Naturheilkd. 2001;8(4):207-212. https://doi.org/10.1159/000057223.; Schmolz M, Weiser M. Wirkungen eines Antihomotoxikums auf das Immunsystem des Menschen. Biol Med. 2001;30:132-135.; Scalia RA, Dolci JE, Ueda SM, Sassagawa SM. In vitro antimicrobial activity of Luffa operculata. Braz J Otorhinolaryngol. 2015;81(4):422-430. https://doi.org/10.1016/j.bjorl.2014.07.015.; Silva L, Costa HO, Souza FC, Lopes EM, Ueda SM. Preclinical evaluation of Luffa operculata Cogn. and its main active principle in the treatment of bacterial rhinosinusitis. Braz J Otorhinolaryngol. 2016;84(1):82-88. https://doi.org/10.1016/j.bjorl.2016.11.004.; Карпищенко СА, Колесникова ОМ. Биорегуляционная терапия в лечении острых и хронических ринитов. РМЖ. 2018;10(2):75-78. Режим доступа: https://www.rmj.ru/articles/otorinolaringologiya/Bioregulyacionnaya_terapiya_v_lechenii_ostryh_i_hronicheskih_rinitov/.

  3. 3
    Academic Journal

    Πηγή: Meditsinskiy sovet = Medical Council; № 22 (2023); 110-120 ; Медицинский Совет; № 22 (2023); 110-120 ; 2658-5790 ; 2079-701X

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/7998/7087; Durán Poveda M, Suárez-de-la-Rica A, Cancer Minchot E, Ocón Bretón J, Sánchez Pernaute A, Rodríguez Caravaca G. The Prevalence and Impact of Nutritional Risk and Malnutrition in Gastrointestinal Surgical Oncology Patients: A Prospective, Observational, Multicenter, and Exploratory Study. Nutrients. 2023;15(14):3283. https://doi.org/10.3390/nu15143283.; Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48. https://doi.org/10.1016/j.clnu.2016.07.015.; Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(5):371–385. https://doi.org/10.1093/jnci/djr556.; Ravasco P, Monteiro-Grillo I, Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr. 2012;96(6):1346–1353. https://doi.org/10.3945/ajcn.111.018838.; Baracos VE. Cancer-associated malnutrition. Eur J Clin Nutr. 2018;72(9):1255–1259. https://doi.org/10.1038/s41430-018-0245-4.; Guenter P, Abdelhadi R, Anthony P, Blackmer A, Malone A, Mirtallo JM et al. Malnutrition diagnoses and associated outcomes in hospitalized patients: United States, 2018. Nutr Clin Pract. 2021;36(5):957–969. https://doi.org/10.1002/ncp.10771.; Brown T, Edwards A, Pashley A, Lehn B, Vasani S, Hodge R, Bauer J. Nutritional status and post-operative complications in patients undergoing surgery for advanced pharyngeal or laryngeal cancer. Eur Arch Otorhinolaryngol. 2023;280(12):5531–5538. https://doi.org/10.1007/s00405-023-08139-x.; Shpata V, Prendushi X, Kreka M, Kola I, Kurti F, Ohri I. Malnutrition at the time of surgery affects negatively the clinical outcome of critically ill patients with gastrointestinal cancer. Med Arch. 2014;68(4):263–267. https://doi.org/10.5455/medarh.2014.68.263-267.; Bossi P, Delrio P, Mascheroni A, Zanetti M. The Spectrum of Malnutrition/ Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021;13(6):1980. https://doi.org/10.3390/nu13061980.; Хомяков ВМ, Хороненко ВЭ, Ермошина АД. Проблема нутритивной недостаточности и методы ее коррекции у больных со злокачественными опухолями пищевода и желудка. Онкология. Журнал им. П.А. Герцена. 2016;5(5):33–37. https://doi.org/10.17116/onkolog20165533-37.; Снеговой АВ, Бесова НС, Веселов АВ, Кравцов СА, Ларионова ВБ, Сельчук ВЮ и др. Практические рекомендации по нутритивной поддержке у онкологических больных. Злокачественные опухоли. 2016;(4s2):434–450. Режим доступа: https://rosoncoweb.ru/standarts/RUSSCO/2016/40.pdf.; Jie B, Jiang ZM, Nolan MT, Zhu SN, Yu K, Kondrup J. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition. 2012;28(10):1022–1027. https://doi.org/10.1016/j.nut.2012.01.017.; Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clin Nutr. 2019;38(1):1–9. https://doi.org/10.1016/j.clnu.2018.08.002.; Лейдерман ИН, Грицан АИ, Заболотских ИБ, Ломидзе СВ, Мазурок ВА, Нехаев ИВ и др. Периоперационная нутритивная поддержка. Клинические рекомендации. Вестник интенсивной терапии имени А.И. Салтанова. 2018;(3):5–21. https://doi.org/10.21320/1818-474X-2018-3-5-21.; Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017;36(3):623–650. https://doi.org/10.1016/j.clnu.2017.02.013.; Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014;101(10):1209–1229. https://doi.org/10.1002/bjs.9582.; Li Z, Bai B, Zhao Y, Yu D, Lian B, Liu Y, Zhao Q. Severity of complications and long-term survival after laparoscopic total gastrectomy with D2 lymph node dissection for advanced gastric cancer: A propensity score-matched, case-control study. Int J Surg. 2018;54(Pt A):62–69. https://doi.org/10.1016/j.ijsu.2018.04.034.; Самсонов МА, Покровский АА (ред.). Справочник по диетологии. 2-е изд. М.: Медицина; 1992. 464 с.; Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. https://doi.org/10.1016/S1470-2045(10)70218-7.; Wang LH, Zhu RF, Gao C, Wang SL, Shen LZ. Application of enhanced recovery after gastric cancer surgery: An updated meta-analysis. World J Gastroenterol. 2018;24(14):1562–1578. https://doi.org/10.3748/wjg.v24.i14.1562.; Obukhova O, Kashiya S, Kurmukov I. MON-P100: Metabolic Disorders in Patients with Advanced Gastric Cancer before Antitumor Chemotherapy. Clin Nutr. 2017;36(Suppl. 1):S216. https://doi.org/10.1016/S0261-5614(17)30983-4.; Тер-Ованесов МД, Кукош МЮ, Габоян АС, Левицкий АВ, Зраибиа А. Концепция ускоренной реабилитации в хирургическом лечении рака пищевода и желудка: постановка проблемы. Медицинский алфавит. 2017;1(16):17–22. Режим доступа: https://www.med-alphabet.com/jour/article/view/147.; Cantwell LA, Fahy E, Walters ER, Patterson JM. Nutritional prehabilitation in head and neck cancer: a systematic review. Support Care Cancer. 2022;30(11):8831–8843. https://doi.org/10.1007/s00520-022-07239-4.; Горбунова ЕА, Филькин ГН, Медведева НН, Зуков РА. Влияние энтерального питания на клиническое течение послеоперационного периода у больных раком желудка. Эффективная фармакотерапия. 2021;17(2):30–36. Режим доступа: https://umedp.ru/articles/vliyanie_enteralnogo_pitaniya_na_klinicheskoe_techenie_posleoperatsionnogo_perioda_u_bolnykh_rakom_zh.html.; West MA, Wischmeyer PE, Grocott MPW. Prehabilitation and Nutritional Support to Improve Perioperative Outcomes. Curr Anesthesiol Rep. 2017;7(4):340–349. https://doi.org/10.1007/s40140-017-0245-2.

  4. 4
  5. 5
  6. 6
    Academic Journal

    Πηγή: Meditsinskiy sovet = Medical Council; № 11 (2023); 90-99 ; Медицинский Совет; № 11 (2023); 90-99 ; 2658-5790 ; 2079-701X

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/7624/6767; Roy C.N. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010;(1):276–280. https://doi.org/10.1182/asheducation-2010.1.276.; Madeddu C., Gramignano G., Astara G., Demontis R., Sanna E., Atzeni V., Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Front Physiol. 2018;9:1294. https://doi.org/10.3389/fphys.2018.01294.; Merlini L., Cartenì G., Iacobelli S., Stelitano C., Airoldi M., Balcke P. et al. Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. Cancer Manag Res. 2013;5:205–214. https://doi.org/10.2147/CMAR.S45236.; Naoum F.A. Iron deficiency in cancer patients. Rev Bras Hematol Hemoter. 2016;38(4):325–330. https://doi.org/10.1016/j.bjhh.2016.05.009.; Finberg K.E., Heeney M.M., Campagna D.R., Aydinok Y., Pearson H.A., Hartman K.R. et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40(5):569–571. https://doi.org/10.1038/ng.130.; Natalucci V., Virgili E., Calcagnoli F., Valli G., Agostini D., Zeppa S.D. et al. Cancer Related Anemia: An Integrated Multitarget Approach and Lifestyle Interventions. Nutrients. 2021;13(2):482. https://doi.org/10.3390/nu13020482.; Testa U. Recent developments in the understanding of iron metabolism. Hematol J. 2002;3(2):63–89. https://doi.org/10.1038/sj.thj.6200163.; Brugnara C., Schiller B., Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006;28(5):303–308. https://doi.org/10.1111/j.1365-2257.2006.00812.x.; Busti F., Marchi G., Ugolini S., Castagna A., Girelli D. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel). 2018;11(4):94. https://doi.org/10.3390/ph11040094.; Ludwig H., Van Belle S., Barrett-Lee P., Birgegård G., Bokemeyer C., Gascón P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–2306. https://doi.org/10.1016/j.ejca.2004.06.019.; Thomas M.R., Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood. 2021;137(10):1310–1317. https://doi.org/10.1182/blood.2019003810.; Birgegård G., Aapro M.S., Bokemeyer C., Dicato M., Drings P., Hornedo J. et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl. 1):3–11. https://doi.org/10.1159/000083128.; Schwartz R.N. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm. 2007;64(3 Suppl. 2):S5–S30. https://doi.org/10.2146/ajhp060601.; Crawford J., Cella D., Cleeland C.S., Cremieux P.Y., Demetri G.D., Sarokhan B.J. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95(4):888–895. https://doi.org/10.1002/cncr.10763.; Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–7810. https://doi.org/10.1074/jbc.M008922200.; Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., Loréal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811–7819. https://doi.org/10.1074/jbc.M008923200.; Weinstein D.A., Roy C.N., Fleming M.D., Loda M.F., Wolfsdorf J.I., Andrews N.C. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100(10):3776–3781. https://doi.org/10.1182/blood-2002-04-1260.; Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461–2463. https://doi.org/10.1182/blood-2002-10-3235.; Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271–1276. https://doi.org/10.1172/JCI20945.; Kader A.S., Lim J.T., Berthelet E., Petersen R., Ludgate D., Truong P.T. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol. 2007;30(5):492–497. https://doi.org/10.1097/01.coc.0000264177.66369.18.; Détivaud L., Nemeth E., Boudjema K., Turlin B., Troadec M.B., Leroyer P. et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood. 2005;106(2):746–748. https://doi.org/10.1182/blood-2004-12-4855.; Macciò A., Madeddu C., Massa D., Mudu M.C., Lusso M.R., Gramignano G. et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005;106(1):362–367. https://doi.org/10.1182/blood-2005-01-0160.; Schaer D.J., Buehler P.W., Alayash A.I., Belcher J.D., Vercellotti G.M. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8):1276–1284. https://doi.org/10.1182/blood-2012-11-451229.; Sasu B.J., Cooke K.S., Arvedson T.L., Plewa C., Ellison A.R., Sheng J. et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17):3616–3624. https://doi.org/10.1182/blood-2009-09-245977.; Baker R.D., Greer F.R. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0–3 years of age). Pediatrics. 2010;126(5):1040–1050. https://doi.org/10.1542/peds.2010-2576.; Rizzo J.D., Brouwers M., Hurley P., Seidenfeld J., Arcasoy M.O., Spivak J.L. et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996–5010. https://doi.org/10.1200/JCO.2010.29.2201.; Xu H., Xu L., Page J.H., Cannavale K., Sattayapiwat O., Rodriguez R., Chao C. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013. Clin Epidemiol. 2016;8:61–71. https://doi.org/10.2147/CLEP.S89480.; Gilreath J.A., Stenehjem D.D., Rodgers G.M. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203–212. https://doi.org/10.1002/ajh.23628.; Hashemi S.M., Mashhadi M.A., Mohammadi M., Ebrahimi M., Allahyari A. Absolute and Functional Iron Deficiency Anemia among Different Tumors in Cancer Patients in South Part of Iran, 2014. Int J Hematol Oncol Stem Cell Res. 2017;11(3):192–198. Available at: https://pubmed.ncbi.nlm.nih.gov/28989585/; Estiri M., Estiri B., Fallah A., Aghazadeh M., Sedaqati A., Abdollahi A. et al. Therapeutic Effects of Mesenchymal Stem Cells Expressing Erythropoietin on Cancer-Related Anemia in Mice Model. Curr Gene Ther. 2022;22(5):406–416. https://doi.org/10.2174/1566523222666220405134136.

  7. 7
    Academic Journal

    Συγγραφείς: M. V. Putilina, М. В. Путилина

    Πηγή: Meditsinskiy sovet = Medical Council; № 3 (2023); 17-23 ; Медицинский Совет; № 3 (2023); 17-23 ; 2658-5790 ; 2079-701X

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/7407/6624; Zhou D., Meng R., Li S.J., Ya J.Y., Ding J.Y., Shang S.L. et al. Advances in chronic cerebral circulation insufficiency. CNS Neurosci Ther. 2018;24(1):5–17. https://doi.org/10.1111/cns.12780.; Feigin V.L., Stark B.A., Johnson C.O., Roth G.A., Bisignano C., Anderson J.A. et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the GlobalBurden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. https://doi.org/10.1016/S1474-4422(21)00252-0.; Tong X., Yang Q., Ritchey M.D., George M.G., Jackson S.L., Gillespie C., Merritt R.K. The Burden of Cerebrovascular Disease in the United States. Prev Chronic Dis. 2019;16:E52. https://doi.org/10.5888/pcd16.180411.; Parfenov V.A. Diagnosis and treatment of chronic cerebrovascular disease, use of pentoxifylline. Neurology, neuropsychiatry, psychosomatics. 2016;8(3):4–9. https://doi.org/10.14412/2074-2711-2016-3-4-9.; Путилина М.В. Нейропротекторная терапия хронической ишемии головного мозга. Врач. 2008;(8):27–32. Режим доступа: https://www.elibrary.ru/download/elibrary_12952445_20568520.pdf.; Путилина М.В. Эндотелий – мишень для новых терапевтических стратегий при сосудистых заболеваниях головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(10):122–130. https://doi.org/10.17116/jnevro2017117101122-130.; Golanov E., Regnier-G olanov A., Britz G. Multifactorial neuroprotection: Does the brain have an answer? Conditioning Medicine. 2019;2(2):75–89. Available at: https://www.researchgate.net/publication/332971133_Conditioning_Medicine_Multifactorial_neuroprotection_Does_the_brain_have_an_answer.; Hannan M.A., Dash R., Sohag A.A.M., Haque M.N., Moon I.S. Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System. Front Mol Neurosci. 2020;(13):116. https://doi.org/10.3389/fnmol.2020.00116.; Favreault M.M., Johnson R.W. The Risk and Costs of Severe Cognitive Impairment at Older Ages: Literature Review and Projection Analyses. Urban Institute. 2021. Available at: https://aspe.hhs.gov/reports/risk-costs-severecognitive-impairment-older-ages-literature-review-projection-analyses-0.; Dutta R. Central nervous system diseases associated with blood brain barrier breakdown - A Comprehensive update of existing literature. J Neurosci Neurol Disord. 2020;4:053–062. https://doi.org/10.29328/journal.jnnd.1001035.; Sweeney M.D., Zhao Z., Montagne A., Nelson A.R., Zlokovic B.V. Blood- Brain Barrier: From Physiology to Disease and Back. Physiol Rev. 2019;99(1):21–78. https://doi.org/10.1152/physrev.00050.2017.; Crockett A.M., Ryan S.K., Vásquez A.H., Canning C., Kanyuch N., Kebir H. et al. Disruption of the blood- brain barrier in 22q11.2 deletion syndrome. Brain. 2021;144(5):1351–1360. https://doi.org/10.1093/brain/awab055.; Giacobbo L.B., Doorduin J., Klein H.C., Dierckx R.A.J.O., Bromberg E., de Vries E.F.J. Brain- Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2019;56(5):3295–3312. https://doi.org/10.1007/s12035-018-1283-6.; Profaci C.P., Munji R.N., Pulido R.S., Daneman R. The blood-b rain barrier in health and disease: Important unanswered questions. J Exp Med. 2020;217(4):e20190062. https://doi.org/10.1084/jem.20190062.; Путилина М.В. Нейропластичность как основа ранней реабилитации пациентов после инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(12–2):64–69. Режим доступа: https://www.elibrary.ru/pywskz.; Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина; 2001. 328 с. Режим доступа: https://med-books.by/nevrologiya/2350-ishemiya-golovnogo-mozga-gusev-ei-skvorcova-vi-2001-god-328-s.html.; Путилина М.В. Современные представления о болезни мелких сосудов головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(11):65–73. https://doi.org/10.17116/jnevro201911911165.; Громова О.А., Торшин И.Ю., Путилина М.В., Семенов В.А., Рудаков К.В. Выбор нейропротективной терапии у пациентов с хронической ишемией головного мозга с учетом синергизма лекарственных взаимодействий. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(8):42–50. https://doi.org/10.17116/jnevro202012008142.; Хавинсон В.Х. Лекарственные пептидные препараты: прошлое, настоящее, будущее. Клиническая медицина. 2020;98(3):165–177. https://doi.org/10.30629/0023-2149-2020-98-3-165-177.; Zhou X., Smith Q.R., Liu X. Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood- brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(4):e1695. https://doi.org/10.1002/wnan.1695.; Lau J.L., Dunn M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707. https://doi.org/10.1016/j.bmc.2017.06.052.; Soudy R., Kimura R., Patel A. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model. Sci Rep. 2019;9(1):10942. https://doi.org/10.1038/s41598-019-47255-9.; Камчатнов П.Р., Абусуева Б.А., Ханмурзаева С.Б., Митяева Е.В., Чипова Д.Т., Малашенков Н.Д. Результаты оценки эффективности применения препарата Целлекс у пациентов с болезнью мелких сосудов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(1):67–74. https://doi.org/10.17116/jnevro202312301167.; Абусуева Б.А., Евзельман М.А, Камчатнов П.Р., Умарова Х.Я. Применение препарата Целлекс у пациентов с хронической ишемией головного мозга и умеренными когнитивными нарушениями. Нервные болезни. 2016;2:29–34. Режим доступа: https://cyberleninka.ru/article/n/primenenie-preparata-tselleks-u-patsientov-s-hronicheskoy-ishemieygolovnogo- mozga-i-umerennymi- kognitivnymi-narusheniyami.; Коваленко А.В., Сафронова М.Н. Влияние целлекса на восстановление когнитивных и речевых нарушений в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(1):40–44.; Tanaka M., Vécsei L. Editorial of Special Issue Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection. Int J Mol Sci. 2022;23(13):6991. https://doi.org/10.3390/ijms23136991.; Путилина М.В. Коморбидный пациент в реальной клинической практике. Consilium Medicum. 2017;19(2):71–79. Режим доступа: https://journals.eco-vector.com/2075-1753/article/view/94738?ysclid=lecr0crssr470786300.

  8. 8
  9. 9
    Academic Journal

    Πηγή: Head and Neck Tumors (HNT); Том 10, № 3 (2020); 12-18 ; Опухоли головы и шеи; Том 10, № 3 (2020); 12-18 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2020-10-3

    Περιγραφή αρχείου: application/pdf

    Relation: https://ogsh.abvpress.ru/jour/article/view/556/433; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2019. 250 с. Доступно по: https://glavonco.ru/cancer_register/Забол_2018_Электр.pdf.; Choksi P., Papaleontiou M., Guo C. et al. Skeletal complications and mortality in thyroid cancer: a population-based study. J Clin Endocrinol Metab 2017;102(4): 1254–60. DOI:10.1210/jc.2016-3906.; Califano I., Deutsch S., Löwenstein A. et al. Outcomes of patients with bone metastases from differentiated thyroid cancer. Arch Endocrinol Metab 2018;62(1):14–20. DOI:10.20945/2359-3997000000004.; Orita Y., Sugitani I., Matsuura M. et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery 2010;147(3):424–31. DOI:10.1016/j.surg.2009.10.009.; Andrade F., Probstner D., Decnop M. et al. The impact of zoledronic acid and radioactive iodine therapy on morbimortality of patients with bone metastases of thyroid cancer derived from follicular cells. Eur Thyroid J 2019;8(1):46–55. DOI:10.1159/000493190.; Iñiguez-Ariza N.M., Bible K.C., Clarke B.L. Bone metastases in thyroid cancer. J Bone Oncol 2020;21:100282. DOI:10.1016/j.jbo.2020.100282.; Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998;19(1):18–54. DOI:10.1210/edrv.19.1.0323.; Osorio M., Moubayed S.P., Su H., Urken M.L. Systematic review of site distribution of bone metastases in differentiated thyroid cancer. Head Neck 2017;39(4):812–8. DOI:10.1002/hed.24655.; Klein U., von Figura K. Characterization of dermatan sulfate in mucopolysaccharidosis VI. Evidence for the absence of hyaluronidase-like enzymes in human skin fibroblasts. Biochim Biophys Acta 1980;630(1):10–4. DOI:10.1016/0304-4165(80)90131-2.; Grávalos C., Rodríguez C., Sabino A. et al. SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol 2016;18(12):1243–53. DOI:10.1007/s12094-016-1590-1.; Harvey H.A., von Reyn Cream L. Biology of bone metastases: causes and consequences. Clin Breast Cancer 2007;7 Suppl 1:S7–13. DOI:10.3816/cbc.2007.s.001.; Russell R.G., Rogers M.J., Frith J.C. et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999;14 Suppl 2:53–65. DOI:10.1002/jbmr.5650140212.; Frank A.J., Moll J.М., Hort J.F. A comparison of three ways of measuring pain. Rheumatol Rehabil 1982;21(4):211–7. DOI:10.1093/rheumatology/21.4.211.; Al Rahabi M.K., Ghabbani H.M. Clinical impact of bisphosphonates in root canal therapy. Saudi Med J 2018;39(3):232–8. DOI:10.15537/smj.2018.3.20923.; Rosen L.S., Gordon D., Tchekmedyian N.S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer 2004;100(12):2613–21. DOI:10.1002/cncr.20308.; Orita Y., Sugitani I., Takao S. et al. Prospective evaluation of zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Ann Surg Oncol 2015;22(12):4008–13. DOI:10.1245/s10434-015-4497-0.; https://ogsh.abvpress.ru/jour/article/view/556

  10. 10
    Academic Journal

    Συνεισφορές: Мерц Фарма, ООО

    Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 10, No 4 (2018); 81-87 ; Неврология, нейропсихиатрия, психосоматика; Vol 10, No 4 (2018); 81-87 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2018-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/1001/816; Petersen RC, Stevens JC, Ganguli M, et al. Mild cognitive impairment (an evidence-based review). Neurology. 2001 May 8;56(9):1133-42.; Petersen RC. Mild cognitive impairment as a diagnostic entity. JIntern Med. 2004 Sep;256(3): 183-94.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 106 с.; Парфенов ВА, Неверовский ДВ. Ведение пациентов с дисциркуляторной энцефалопатией в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2015; 7(1):37-42. doi:10.14412/2074-2711-2015-1-37-42; Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12.; Kivipelto M, Helkala EL, Laakso M, et al. Middle life vascular risk factors and Alzheimer’s disease in later life: longitudinal population based study. BMJ. 2001 Jun 16;322(7300):1447-51.; Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. In: Rockwood K, Gauthier S, editors. Dementia therapeutic research. London a New York: Taylor a Francis; 2006. P. 189-212.; Iqbal K, Winblad B, Nishumura T, et al, editors. Alzheimer's disease: biology, diagnosis and therapeutics. J. Willey and sons; 1997. 831 p.; Преображенская ИС. Постинсультные когнитивные расстройства: причины, клинические проявления, лечение. Фарматека. 2013;(9):49-53. [Preobrazhenskaya IS. Poststroke cognitive disorders: causes, clinical manifestations, treatment. Farmateka. 2013;(9):49-53. (In Russ.)].; Barba R, Castro MD, del Mar Morin M, et al. Prestroke dementia. Cerebrovasc Dis. 2001;11(3):216-24.; Hachinski V. Vascular dementia: radical redefinition. In: Carlson LA, Gottfries SG; Winblad B, editors. Vascular dementia: etiology, pathogenesis and clinical aspects. S. Karger; 1994. P. 2-4.; Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi:10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.; Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. Sci Rep. 2016 Feb 15;6:20873. doi:10.1038/srep20873.; O’Brien J, Ames D, Gustafson L, et al, editors. Cerebrovascular disease, cognitive impairment and dementia. Second edition. Martin Dunitz; 2004.; Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to cognitive impairment and dementia: A Statement for healthcare Professionals from the American Heart Association / American Stroke Association. Stroke. 2011 Sep;42(9):2672-713. doi:10.1161/ STR.0b013e3182299496. Epub 2011 Jul 21.; Парфенов ВА. Профилактика болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2011;3(3):8-13.; Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004 Jan;128(1):32-8.; Hulette CM. Brain banking in the United States. JNeuropathol Exp Neurol. 2003 Jul; 62(7):715-22.; Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003 Apr;60(4):569-75.; Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35.; Kim GH, Lee JH, Seo SW, et al. Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiol Aging. 2015 Jan;36(1):485-91. doi:10.1016/j.neurobiolag-ing.2014.08.009. Epub 2014 Sep 28.; Захаров ВВ. Медикаментозная терапия в восстановительном периоде инсульта. Фар-матека. 2015;(9):80-7.; Butefisch CM. Plasticity in the human cerebral cortex: lessons from the normal brain and from stroke. Neuroscientist. 2004 Apr;10(2):163-73.; L0mo T. The discovery of long-term potentiation. Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):617-20.; Ziemann U, Muellbacher W, Hallett M, Cohen LG. Modulation of practice-dependent plasticity in human motor cortex. Brain. 2001 Jun;124(Pt 6):1171-81.; Захаров ВВ. Глутаматергическая терапия в восстановительном периоде после ишемического инсульта. Эффективная фармакотерапия. Неврология. 2014;(4):6-16.; Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin Interv Aging. 2009;4:367-77. Epub 2009 Oct 12.; Areosa Sastre A, Sheriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154.; Orgogozo JM, Rigaud AS, Sto ffler A, et al. Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia a Randomized, Placebo-Controlled Trial (MMM 300). Stroke. 2002 Jul;33(7):1834-9.; Wilcock G, Mo bius HJ, Sto ffler A; MMM 500 group. A double-blind, placebo-controlled multicenter study of Memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305.; Левин ОС, Юнищенко НА, Дударова МА. Эффективность акатинола мемантина при умеренно выраженном когнитивном расстройстве. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;(7):36-42.; Яхно НН, Преображенская ИС, Захаров ВВ, Мхитарян ЭА. Эффективность мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал. 2010;15(2): 52-8.; Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD005562. doi:10.1002/14651858.CD005562.pub2.; Martin M, Clare L, Altgassen AM, et al. Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev. 2011 Jan 19; (1):CD006220. doi:10.1002/14651858.CD006220.pub2.; Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2015 Apr 22;(4):CD005381. doi:10.1002/14651858.CD005381.pub4.; Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct; 43-44:38-53. doi:10.1016/j.mam.2015.06.003. Epub 2015 Jun 10.; Науменко АА, Громова ДО, Преображенская ИС. Когнитивный тренинг и реабилитация пациентов с когнитивными нарушениями. Доктор. Ру. 2017;(11):31-8.; Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi:10.1001/arch-neurol.2009.307.; Schmidt W, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013; 35(4):303-12. doi:10.1159/000347061. Epub 2013 Apr 10.; Bherer L. Cognitive plasticity in older adults: effects of cognitive training and physical exercise. Ann N YAcad Sci. 2015 Mar;1337:1-6. doi:10.1111/nyas.12682.; Bherer L, Kramer AF, Peterson MS, et al. Transfer effects in task-set cost and dual-task cost after dual-task training in older and younger adults: further evidence for cognitive plasticity in attentional control in late adulthood. Exp Aging Res. 2008 Jul-Sep;34(3): 188-219. doi:10.1080/03610730802070068.; Kolb B, Gibb R. Principles of neuroplasticity and behavior. In: Stuss D, Winocur G, Robertson I, editors. Cognitive neurorehabilitation: Evidence and Application. New York: Cambridge University Press; 2008. P. 6-21.; Wilson RS, Scherr PA, Schneider JA, et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology. 2007 Nov 13; 69(20):1911-20. Epub 2007 Jun 27.; Wada M, Noda Y, Shinagawa S, et al. Effect of Education on Alzheimer’s Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A CrossSectional Study. JAlzheimers Dis. 2018;63(2): 861-869. doi:10.3233/JAD-171168.; Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol. 2011 Jun;68(6):743-52. doi:10.1001/archneurol.2011.125.; Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Arch Neurol. 2011 Jun; 68(6):743-52. doi:10.1001/archneurol.2011.125.; Morris MC, Evans DA, Tangney CC, et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology. 2006 Oct 24;67(8):1370-6.; Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. John Wiley & Sons; 2007. P. 356-60.

  11. 11
  12. 12
    Academic Journal
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    Academic Journal

    Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 6, No 1 (2014); 89-94 ; Неврология, нейропсихиатрия, психосоматика; Vol 6, No 1 (2014); 89-94 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2014-1

    Περιγραφή αρχείου: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/370/379; Мчедлишвили ГИ. Спазм сосудов головного мозга. Тбилиси: Мецниереба; 1977. 182 с. [Mchedlishvili GI. Spazm sosudov golovnogo mozga [Brain angiospasm]. Tbilisi: Metsniereba; 1977. 182 p.]; Бердичевский МЯ. Венозная дисциркуляторная патология головного мозга. Москва: Медицина; 1989. 224 с. [Berdichevskii MYa. Venoznaya distsirkulyatornaya patologiya golovnogo mozga [Venous distsirkulyatorny pathology of a brain]. Moscow: Meditsina; 1989. 224 p.]; Бурцев ЕМ, Сергиевский СБ, Асратян СА. Варианты церебральной артериальной и венозной ангиоархитектоники при дисциркуляторной энцефалопатии. Журнал неврологии и психиатрии им.; С.С. Корсакова. 1999;99(4):45–7. [Burtsev EM, Sergievskii SB, Asratyan SA. Options cerebral arterial and venous angioarkhitektonik at distsirkulyatorny encephalopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1999;99(4):45–7. (In Russ.)]; Исайкин АИ, Горбачева ФЕ. Состояние внутримозговой (артериальной и венозной) и каротидной гемодинамики у больных с тяжелой легочной патологией. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999;99(7):12–5. [Isaikin AI, Gorbacheva FE. State intracerebral (arterial and venous) and carotid haemo dynamics at patients with heavy pulmonary pathology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1999;99(7):12–5. (In Russ.)]; Лесницкая ВЛ, Яровая ИМ, Петровский ИН, Завгородняя ГП. Венозная система головного и спинного мозга в норме и патологии. Москва: Медицина; 1970. 222 c. [Lesnitskaya VL, Yarovaya IM, Petrovskii IN, Zavgorodnyaya GP. Venoznaya sistema golovnogo i spinnogo mozga v norme i patologii [Venous system of a head and spinal cord in norm and pathology]. Moscow: Meditsina; 1970. 222 p.]; Астапенко АВ, Короткевич ЕА, Антиперович ТГ и др. Тромбоз церебральных вен и синусов. Медицинские новости. 2004;8:48–52. [Astapenko AV, Korotkevich EA, Antiperovich TG, et al. Thrombosis of cerebral veins and sine. Meditsinskie novosti. 2004;8:48–52.] (In Russ.)]; Бабенков НВ. Нарушения венозного кровообращения мозга: патогенез, клиника, течение, диагностика. Журнал невропатологии и психиатрии им. С.С. Корсакова. 1984;84(2):281–8.[ Babenkov NV. Violations of venous blood circulation of a brain: патогенез, clinic, current, diagnostics. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 1984;84(2):281–8. (In Russ.)]; Богданов ЭИ, Заббарова АТ. Церебральные венозные тромбозы. Неврологический вестник. Журнал им. В.И. Бехтерева. 2003;XXXV(1–2):52–7. [Bogdanov EI, Zabbarova AT. Cerebral venous thromboses. Nevrologicheskii vestnik. Zhurnal im. V.I. Bekhtereva. 2003;XXXV(1–2):52–7. (In Russ.)]; Виберс Д, Фейгин В, Браун. Руководство по цереброваскулярным заболеваниям. Пер. с англ. Москва: БИНОМ; 1999. 672 с. [Vibers D, Feigin V, Braun R. Rukovodstvo po tserebrovaskulyarnym zabolevaniyam [Guide to tserebrovaskulyarny diseases]. Translation from English. Moskva: BINOM; 1999. 672 p.]; Медведева ЛА, Дутикова ЕФ, Щербакова НЕ и др. Комплексная патогенетическая терапия головных болей, обусловленных дегенеративно-дистрофическими изменениями шейного отдела позвоночника с явлениями венозного застоя. Журнал неврологии и психиатрии им С.С. Корсакова. 2007;107(11):36–41. [Medvedeva LA, Dutikova EF, Shcherbakova NE, et al. The complex pathogenetic therapy of headache caused by the degenerative dystrophic changes of the cervical spine with signs of passive congestion. Zhurnal nevrologii i psikhiatrii im S.S. Korsakova. 2007;107(11):36–41. (In Russ.)]; Никифоров АС, Гусев ЕИ. Частная неврология. 2-е изд. Москва: ГЕОТАР-Медиа; 2013. 768 с. [Nikiforov AS, Gusev EI. Chastnaya nevrologiya [Private neurology]. 2nd ed. Moscow: GEOTAR-Media; 2013. 768 p.]; Тул ДФ. Сосудистые заболевания головного мозга. Перевод с анг. Гусева ЕИ, Гехт АБ, редакторы. 6-е изд. Москва: ГЕОТАР-Медиа; 2007. 608 с. [Tul DF. Sosudistye zabolevaniya golovnogo mozga [Vascular diseases of a brain]. Translation from English. Guseva EI, Gekht AB, editors. 6th ed. Moscow: GEOTAR-Media; 2007. 608 p.]; Ржеусская ГВ, Листопадов ЮИ, Кириенков ИС и др. Использование антистакса при лечении дисциркуляторной энцефалопатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(9):60–3. [Rzheusskaia GV, Listopadov IuI, Kireenkov IS, et al. The use of antistax in the treatment of discirculatory encephalopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(9):60–3. (In Russ.)]; Холоденко МИ. Расстройства венозного кровообращения в мозгу. Москва: Медицина; 1963. 226 с. [Kholodenko MI. Rasstroistva venoznogo krovoobrashcheniya v mozgu [Disorders of venous blood circulation in a brain]. Moscow: Meditsina; 1963. 226 p.]; Шумилина МВ. Нарушения венозного церебрального кровообращения с сердечно-сосудистой патологией. Автореф. дис. д-ра мед. наук. Москва; 2002. 44 с. [Shumilina MV. Narusheniya venoznogo tserebral'nogo krovoobrashcheniya s serdechno-sosudistoi patologiei [Violations of venous cerebral blood circulation with cardiovascular pathology].; Moscow; 2002. 44 s.]; Крыжановский ГН. Общая патофизиология нервной системы. Москва: Медицина; 1997. 352 с. [Kryzhanovskii GN. Obshchaya patofiziologiya nervnoi sistemy [General pathophysiology of nervous system]. Moskva: Meditsina; 1997. 352 p.]; Яхно НН, редактор. Дисциркуляторная энцефалопатия. Москва: РКИ Соверо-пресс; 2004. 32 с. [Yakhno NN, editor. Distsirkulyatornaya entsefalopatiya. [Distsirkulyatorny encephalopathy.].; Moscow: RKI Sоvero-press; 2004. 32 p.]; Манвелов ЛС, Кадыков АВ. Венозная недостаточность мозгового кровообращения. Атмосфера. Нервные болезни. 2007;2:18–21. [Manvelov LS, Kadykov AV. Venous insufficiency of brain blood circulation. Atmosfera. Nervnye bolezni. 2007;2:18–21. (In Russ.)]; Неймарк ЕЗ. Тромбозы внутричерепных синусов и вен. Москва: Медицина; 1975. [Neimark EZ. Trombozy vnutricherepnykh sinusov i ven [Thromboses of intra cranial sine and veins]. Mosсow: Meditsina; 1975.]; Черний ВИ, Шраменко ЕК, Кузнецова ИВ. Тромбозы и эмболии. Медицина неотложных состояний. 2007;1(8):8–16. [Chernii VI, Shramenko EK, Kuznetsova IV. [Thromboses and embolisms]. Meditsina neotlozhnykh sostoyanii. 2007;1(8):8–16. (In Russ.)]; Bauer K, Rosendaal F, Heit J. Hypercoagulability: too many tests, too much conflicting data. Hematology Am Soc Hematol Educ Program. 2002;353–68. DOI: http://dx.doi.org/10.1182/asheducation-2002.1.353.; Путилина МВ, Ермошкина НЮ. Венозная энцефалопатия. Возможности диагностики и лечения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(9):89–93. [Putilina MV, Ermoshkina NIu. Venous encephalopathy. Possibilities of diagnosis and treatment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;113(9):89–93. (In Russ.)]; Фурсова ЛА. Тромбозы церебральных вен и синусов. ARS Medicine. 2009;3(13):106–18. [Fursova LA. Trombozy tserebral'nykh ven i sinusov [Thromboses of cerebral veins and sine]. ARS Medicine. 2009;3(13):106–18.]; Weiner WJ, Goetz CG, Shin RK, Lewis SL, editors. Neurology for the Non-Neurologist.; th ed. Lippincott Williams & Wilkins, 2010. 652 p.; Meyer JS, Xu G, Thornby J, et al. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer’s disease? Stroke. 2002;33(8):1981–5. DOI: http://dx.doi.org/10.1161/01. STR.0000024432.34557.10.; Wilcock G, Rockwood K. Diagnosis and management of dementia. A manual for memory disorders team. Oxford, NY: Oxford University Press; 1999. 251 p.; Felisati G, Annoni K, Battaglia A. Final results based on a new semiquantitative symptom evaluation of an open multicentric study with nicergoline on dizziness in aged people. 15th World Congress of Otorhinolaryngology Head and Neck Surgery. Instanbul, Turkey. Abstract Book. 1993;34:110.; Winbland В, Fioravanti M, Dolezal T, et al. Therapeutic use of Nicergoline. Clin Drug Investig. 2008;28(9):533–52. DOI: http://dx.doi.org/10.2165/00044011-200828090-00001.; Nappi G, Bono G, Merlo P, et al. Long-term nicergoline treatment of mild to moderate senile dementia. results of a multicantre, double-blind, placebo-controlled study. Clin Drug Investig. 1197;13(6):308–17. DOI: http://dx.doi.org/10.2165/00044011-199713060-00003.; Rockwood K, Black S,, Feldman H. Progression to dementia in patients with vascular cognitive impairment without dementia: a multiРcentre clinical study. In: 2nd Congress of the International Society for Vascular Behavioural and Cognitive Disorders (Vas–Cog). Abstract book. Florence; 2005. 105 p.

  19. 19
  20. 20